Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$7,645 Mln
Revenue (TTM)
$7,505 Mln
Net Profit (TTM)
$0 Mln
ROE
0.1 %
ROCE
-- %
P/E Ratio
13.8
P/B Ratio
0.9
Industry P/E
--
EV/EBITDA
8.4
Div. Yield
2 %
Debt to Equity
1.7
Book Value
$7.7
EPS
$0.6
Face value
--
Shares outstanding
258,223,736
CFO
$6,327.82 Mln
EBITDA
$11,809.86 Mln
Net Profit
$4,583.81 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Grifols S.A. - ADR
| -18.7 | -16.2 | -16.6 | -2.4 | 3.1 | -14.6 | -6.7 |
|
BSE Sensex
| -12.5 | -11.1 | -13.4 | -3.7 | 8.5 | 8.2 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Grifols S.A. - ADR
| 25.7 | -35.4 | 36.0 | -24.3 | -37.5 | -19.9 | 29.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Grifols S.A. - ADR
|
7.6 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 |
| 11.3 | 3,410.4 | 510.2 | 146.9 | 37.2 | 35.6 | 23.9 | 7.2 | |
| 12.1 | 3,722.1 | 3,018.8 | 72.1 | 12.6 | -80 | 53.8 | 86.1 | |
| 158.8 | 8,027.0 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.0 | |
| 68.5 | 13,287.4 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 33.8 | 3,684.8 | 761.4 | 99.7 | 7.3 | 15 | 42.2 | 5.7 | |
| 13.5 | 11,772.8 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 19.6 | 3.0 | |
| 24.9 | 11,922.1 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.9 | |
| 201.7 | 4,084.1 | 268.1 | 124.5 | 60.0 | 13.5 | 33.5 | 4.0 | |
| 35.2 | 3,208.3 | 158.3 | -68.9 | -29.3 | -113 | -- | 71.7 |
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma,... Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain. Read more
Executive Chairman
Mr. Thomas H. Glanzmann
Executive Chairman
Mr. Thomas H. Glanzmann
Headquarters
Barcelona
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Grifols SA - ADR is $7.60 (NASDAQ) as of 24-Mar-2026 16:00 EDT. Grifols SA - ADR has given a return of 3.12% in the last 3 years.
The P/E ratio of Grifols SA - ADR is 13.81 times as on 20-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
16.48
|
1.21
|
|
2024
|
32.26
|
0.86
|
|
2023
|
185.51
|
1.46
|
|
2022
|
31.20
|
1.02
|
|
2021
|
--
|
--
|
The 52-week high and low of Grifols SA - ADR are Rs 11.14 and Rs 6.19 as of 25-Mar-2026.
Grifols SA - ADR has a market capitalisation of $ 7,645 Mln as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Grifols SA - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.09
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.